Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Kojic Acid and Tranexamic Acid (topical) are closely matched across evidence, studies, and safety.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (1)
Outcomes where both Kojic Acid and Tranexamic Acid (topical) have evidence — compare verdict strength side-by-side.
Topical cosmetic only. Kojic acid is typically used at roughly 1-2% in leave-on serums or creams (or as the more stable kojic acid dipalmitate), applied to areas of hyperpigmentation once or twice daily, often alongside other brighteners and daily sunscreen. There is no oral, injectable, or systemic dose — it is not ingested. This library does not provide an ingestion protocol.
any
Leave-on topical serum or cream (≈1-2% kojic acid, or kojic acid dipalmitate)
Topical use, typically ~2-5% tranexamic acid in a serum applied to areas of melasma once or twice daily, alongside daily sunscreen. There is no oral or systemic dose in this cosmetic context — the ingested medication is a separate prescription use with clotting-risk considerations. This library does not provide an ingestion protocol.
any
Leave-on topical serum (≈2-5% tranexamic acid)
Throughout
8-12 weeks
Throughout
1-12 months
Throughout
8-12 weeks
Throughout
Throughout
Treatment of melasma using kojic acid in a gel containing hydroquinone and glycolic acid.
Dermatol Surg (1999) · Rct · n=40
Split-face randomized design in 40 women with epidermal melasma: 2% kojic acid added to a 10% glycolic acid + 2% hydroquinone base vs the base alone
Efficacy and safety of topical agents in the treatment of melasma: What's evidence? A systematic review and meta-analysis.
J Cosmet Dermatol (2023) · Meta analysis
Pooled 45 efficacy studies (2359 patients) of topical melasma treatments using MASI standardised mean differences
Kojic Acid vis-a-vis its Combinations with Hydroquinone and Betamethasone Valerate in Melasma: A Randomized, Single Blind, Comparative Study.
Indian J Dermatol (2013) · Rct · n=80
80 melasma patients randomized over 12 weeks to kojic acid 1% alone, kojic acid + hydroquinone 2%, kojic acid + betamethasone, or all three (MASI-assessed)
Topical tranexamic acid as a promising treatment for melasma.
J Res Med Sci (2014) · Rct · n=50
Double-blind 12-week split-face RCT in 50 women: 3% topical TXA on one side vs 3% hydroquinone + 0.01% dexamethasone on the other, twice daily
The effectiveness and safety of 3% tranexamic acid cream vs. 4% hydroquinone cream for mixed-type melasma in skin of color: a double-blind, split-face, randomized controlled trial.
Acta Dermatovenerol Alp Pannonica Adriat (2024) · Rct · n=20
Double-blind 8-week split-face RCT in 20 skin-of-color subjects comparing 3% topical TXA cream vs 4% hydroquinone cream
Tranexamic acid as a therapeutic option for melasma management: meta-analysis and systematic review of randomized controlled trials.
J Dermatolog Treat (2024) · Meta analysis
Meta-analysis of 22 RCTs (1280 patients) of TXA delivered orally, topically, or by injection for melasma
Both Kojic Acid and Tranexamic Acid (topical) are closely matched — the best choice depends on your specific health goals.
Both Kojic Acid and Tranexamic Acid (topical) score equally (70) for even skin tone.
No known interactions between Kojic Acid and Tranexamic Acid (topical) have been documented in our database. However, always consult a healthcare provider before combining supplements.